Cargando…

CYP1B1 as a therapeutic target in cardio-oncology

Cardiovascular complications have been frequently reported in cancer patients and survivors, mainly because of various cardiotoxic cancer treatments. Despite the known cardiovascular toxic effects of these treatments, they are still clinically used because of their effectiveness as anti-cancer agent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carrera, Alexa N., Grant, Marianne K.O., Zordoky, Beshay N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2020
Materias:	Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672255/ https://www.ncbi.nlm.nih.gov/pubmed/33185690 http://dx.doi.org/10.1042/CS20200310

Ejemplares similares

Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2019)

Sexual Dimorphism in Doxorubicin-induced Systemic Inflammation: Implications for Hepatic Cytochrome P450 Regulation
por: Grant, Marianne K.O., et al.
Publicado: (2020)

Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice
por: Grant, Marianne K. O., et al.
Publicado: (2017)

Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice
por: Agostinucci, Kevin, et al.
Publicado: (2023)

Metformin mitigates SASP secretion and LPS-triggered hyper-inflammation in Doxorubicin-induced senescent endothelial cells
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2023)

Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction
por: Grant, Marianne K. O., et al.
Publicado: (2020)

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2022)

The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology
por: Fatunde, Olubadewa A., et al.
Publicado: (2020)

Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2021)

Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
por: Meiners, Becky, et al.
Publicado: (2018)

Editorial: Cardio-oncology: mechanisms and therapeutics
por: Ma, Yan, et al.
Publicado: (2023)

Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice
por: Grant, Marianne K. O., et al.
Publicado: (2019)

Manual of oncologic therapeutics /
Publicado: (1995)

The ESC 2022 Cardio-Oncology Guidelines and the Road Ahead in Cardio-Oncology
por: Cheng, Richard K., et al.
Publicado: (2022)

Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology
por: Liang, Zehua, et al.
Publicado: (2022)

Divergent Cardiac Effects of Angiotensin II and Isoproterenol Following Juvenile Exposure to Doxorubicin
por: Agostinucci, Kevin, et al.
Publicado: (2022)

Bradyarrhythmias in Cardio-Oncology
por: Fonseca, Marta, et al.
Publicado: (2021)

Association between the combined effects of GSTM1 present/null and CYP1A1 MspI polymorphisms with lung cancer risk: an updated meta-analysis
por: Zhang, Wen-Ping, et al.
Publicado: (2020)

Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
por: Albini, Adriana, et al.
Publicado: (2010)

Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer
por: Lopez-Mattei, Juan C., et al.
Publicado: (2021)

A perspective on HPK1 as a novel immuno-oncology drug target
por: Sawasdikosol, Sansana, et al.
Publicado: (2020)

The Heidelberg cardio-oncology unit (COUNT)—a possible blueprint for improved care of cardio-oncological patients
por: Lehmann, L. H., et al.
Publicado: (2021)

The Establishment of the Nordic Cardio-Oncology Society
por: Broberg, Agneta Månsson, et al.
Publicado: (2020)

Cardio-Oncology in Iran
por: Alizadehasl, Azin, et al.
Publicado: (2021)

Cardio-oncology in 2022
por: Dobson, Rebecca
Publicado: (2023)

Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology
por: Mall, Raghvendra, et al.
Publicado: (2022)

Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field
por: Liu, Victor Y., et al.
Publicado: (2018)

Cardio-Oncology and Health Equity: Opportunities for Implementation
por: Johnson, Michelle N.
Publicado: (2023)

Onco-epidemiology of domestic animals and targeted therapeutic attempts: perspectives on human oncology
por: Di Cerbo, Alessandro, et al.
Publicado: (2014)

Cardio-Oncology Considerations in Oncologic Treatment Decisions
por: Fadol, Anecita P.
Publicado: (2022)

Functional variant rs10175368 which affects the expression of CYP1B1 plays a protective role against breast cancer in a Chinese Han population
por: Liu, Jiarui, et al.
Publicado: (2023)

Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology
por: Vadalà, Maria, et al.
Publicado: (2016)

Cardio-oncology: Concepts and practice
por: Cubbon, Richard M., et al.
Publicado: (2016)

New avenues in cardio-oncology
por: Sala, Valentina, et al.
Publicado: (2019)

Hypertension management in cardio-oncology
por: Essa, Hani, et al.
Publicado: (2020)

The Role of Biomarkers in Cardio-Oncology
por: Ananthan, Kajaluxy, et al.
Publicado: (2020)

Cardio-Oncology: Stronger Together
por: Kovacs, Richard J., et al.
Publicado: (2019)

Strain Imaging in Cardio-Oncology
por: Liu, Jennifer E., et al.
Publicado: (2020)

Birth and Maturation of Cardio-Oncology
por: Bhatt, Deepak L.
Publicado: (2019)

My Hope for Cardio-Oncology
por: Ky, Bonnie
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1i4rurh1u9vdqmgj5ca5c6q154